Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Affordable insulin

- PMLiVE

Lilly gets FDA approval for severe alopecia areata treatment for paediatric patients

Treatment with Olumiant resulted in substantial scalp hair regrowth, as well as improvements in eyebrows and eyelashes

- PMLiVE

Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal

The deal focuses on addressing critical unmet medical needs

- PMLiVE

Novo Nordisk UK appoints George Godfrey as Senior Director, Medical & Regulatory

Godfrey previously served as Head of Medical for Respiratory and Immunology for AstraZeneca UK

- PMLiVE

Lilly to acquire Merida Biosciences in deal worth up to $2.875bn

The acquisition is to advance treatments for serious autoimmune and allergic diseases

- PMLiVE

Eli Lilly’s Foundayo authorised by UK MHRA for weight loss and type 2 diabetes

The UK is the first country in Europe to authorise the oral medication

- PMLiVE

Lilly’s olomorasib gets FDA Breakthrough Therapy designation for pancreatic cancer

Around 60,000 people in the US get pancreatic cancer each year, with an estimated 50,000 deaths projected annually

- PMLiVE

Lilly to acquire AtaiBeckley in deal worth $2.8bn

The acquisition will advance therapies for treatment-resistant depression and other mental health conditions

- PMLiVE

Sanofi announces phase 3 study data for infantile-onset Pompe disease

Pompe disease is a rare, progressive neuromuscular disease, with infantile onset being the most aggressive form

- PMLiVE

Sanofi’s Cenrifki approved in Europe for secondary progressive MS without relapses

SPMS is a debilitating stage of MS where patients experience increasing levels of disability

- PMLiVE

Sanofi appoints Paulo Fontoura as Global Head of R&D

Fontoura previously held senior leadership roles at Xaira Therapeutics and Roche

- PMLiVE

Sanofi’s Sarclisa approved by MHRA as UK’s first anti-cancer treatment given via on-body injector

It is the first anticancer treatment in the UK and globally to be administered this way and a first in multiple myeloma

- PMLiVE

Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis

This new option for patients allows for as few as six maintenance injections per year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links